Abstract
Urokinase-type plasminogen activator (uPA) is one of the two physiological serine proteases responsible for the activation of plasminongen to plasmin. uPA activity is regulated by its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), and an expanding list of their interacting proteins. In addition to plasminogen activation, this system also plays important roles in the regulation of many cellular processes including cell proliferation, adhesion and migration. It is beyond reasonable doubt that this enzyme system plays a central role in tumor biology and represents a high potential target for therapeutic intervention of tumor growth and metastasis. During the past fifteen years, crystal structures of uPA and its inhibitors have facilitated the development of uPA inhibitors. Many crystal structures of proteins in the uPA/uPAR system have also been reported recently, especially a series of structures of uPAR and its complexes with vitronectin and uPA, facilitating the development and evaluation of uPAR inhibitors. Recent progress on uPA inhibitors will be summarized in this article. The unique structural features and the druggable potentials of these new structures will also be discussed.
Keywords: uPA, uPAR, SMB crystal structures, inhibitors, crystal structures, inhibitors, serine proteases, plasminogen activation, antagonist, tumor, signaling
Current Drug Targets
Title: Structural Basis for Therapeutic Intervention of uPA/uPAR System
Volume: 12 Issue: 12
Author(s): Jacky Chi Ki Ngo, Longguang Jiang, Zhonghui Lin, Cai Yuan, Zhuo Chen, Xu Zhang, Haiyang Yu, Jundong Wang, Lin Lin and Mingdong Huang
Affiliation:
Keywords: uPA, uPAR, SMB crystal structures, inhibitors, crystal structures, inhibitors, serine proteases, plasminogen activation, antagonist, tumor, signaling
Abstract: Urokinase-type plasminogen activator (uPA) is one of the two physiological serine proteases responsible for the activation of plasminongen to plasmin. uPA activity is regulated by its inhibitors (PAI-1 and PAI-2) and its receptor (uPAR), and an expanding list of their interacting proteins. In addition to plasminogen activation, this system also plays important roles in the regulation of many cellular processes including cell proliferation, adhesion and migration. It is beyond reasonable doubt that this enzyme system plays a central role in tumor biology and represents a high potential target for therapeutic intervention of tumor growth and metastasis. During the past fifteen years, crystal structures of uPA and its inhibitors have facilitated the development of uPA inhibitors. Many crystal structures of proteins in the uPA/uPAR system have also been reported recently, especially a series of structures of uPAR and its complexes with vitronectin and uPA, facilitating the development and evaluation of uPAR inhibitors. Recent progress on uPA inhibitors will be summarized in this article. The unique structural features and the druggable potentials of these new structures will also be discussed.
Export Options
About this article
Cite this article as:
Chi Ki Ngo Jacky, Jiang Longguang, Lin Zhonghui, Yuan Cai, Chen Zhuo, Zhang Xu, Yu Haiyang, Wang Jundong, Lin Lin and Huang Mingdong, Structural Basis for Therapeutic Intervention of uPA/uPAR System, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635911
DOI https://dx.doi.org/10.2174/138945011797635911 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry Optical Imaging of Microvascular Morphology and Perfusion
Current Angiogenesis (Discontinued) An update on the Management and Treatment of Deep Vein Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Vascular Pharmacology Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Inhibitors of the Proteolytic Activity of Urokinase Type Plasminogen Activator
Current Pharmaceutical Design Proteomics and Cardiovascular Disease: An Update
Current Medicinal Chemistry An update on Anti-inflammatory Compounds: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Mechanical Thrombectomy in Acute Ischaemic Stroke: A Review of the Literature, Clinical Effectiveness and Future Use
CNS & Neurological Disorders - Drug Targets Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Spectrophotometric Quantification of Bilirubin in Hemorrhagic Spinal Fluid using an Innovative Algorithm
Medicinal Chemistry Vascular Risk Factors, Vascular Diseases, and Imaging Findings in a Hospital-based Cohort of Mild Cognitive Impairment Types
Current Alzheimer Research CT Virtual Intravascular Endoscopy in the Visualization of Coronary Plaques: A Pictorial Essay
Current Medical Imaging Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) The Genetics of Vascular Complications in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Current Hypertension Reviews Effect of β-Blockers on Perioperative Myocardial Ischemia in Patients Undergoing Noncardiac Surgery
Current Drug Targets Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Hallmarks in the Therapeutic Approach of Aortic Aneurysms: The Main Contributors
Current Pharmaceutical Design